Dimensional Fund Advisors Reduces Gilead Sciences Stake

Institutional investor trims position in biopharmaceutical company

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Dimensional Fund Advisors LP, a major institutional investor, decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund now owns approximately 9.6 million shares of the biopharmaceutical company's stock, valued at over $1 billion.

Why it matters

Gilead Sciences is a prominent biopharmaceutical company known for its antiviral therapies, particularly in the areas of HIV and viral hepatitis. Changes in ownership by major institutional investors can signal shifts in market sentiment and influence the company's stock price performance.

The details

According to the 13F filing, Dimensional Fund Advisors sold 566,769 shares of Gilead Sciences during the third quarter, reducing its total stake in the company to around 9.6 million shares. This represents approximately 0.77% of Gilead's outstanding shares. The fund cited portfolio rebalancing and other investment considerations as the reasons for the reduced position.

  • Dimensional Fund Advisors decreased its Gilead Sciences holdings in the 3rd quarter of 2026.
  • The 13F filing disclosing the reduced stake was submitted on March 4, 2026.

The players

Dimensional Fund Advisors LP

A major institutional investor and asset management firm that decreased its holdings in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The reduction in Dimensional Fund Advisors' Gilead Sciences stake reflects the broader market dynamics and investment considerations that can influence institutional ownership of pharmaceutical companies. While the reasons for the decreased position are not explicitly stated, it highlights the need for investors to closely monitor changes in major shareholders' holdings to better understand the sentiment and potential future performance of Gilead Sciences.